KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Other: 2016-2024

Historic Receivables - Other for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Dec 2024 value amounting to $2.1 million.

  • CRISPR Therapeutics AG's Receivables - Other fell 67.69% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year decrease of 67.69%. This contributed to the annual value of $2.1 million for FY2024, which is 67.69% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Receivables - Other of $2.1 million as of FY2024, which was down 67.69% from $6.5 million recorded in FY2023.
  • CRISPR Therapeutics AG's 5-year Receivables - Other high stood at $11.2 million for FY2022, and its period low was $2.1 million during FY2024.
  • Moreover, its 3-year median value for Receivables - Other was $6.5 million (2023), whereas its average is $6.6 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Receivables - Other soared by 33.33% in 2022 and then tumbled by 67.69% in 2024.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Receivables - Other stood at $10.7 million in 2020, then decreased by 21.50% to $8.4 million in 2021, then spiked by 33.33% to $11.2 million in 2022, then tumbled by 41.96% to $6.5 million in 2023, then tumbled by 67.69% to $2.1 million in 2024.